According to the latest report published by Credence Research, Inc. “Tamoxifen Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the tamoxifen market was valued at USD 675.7 Mn in 2015, and is expected to reach USD 683.6 Mn by 2022, expanding at a CAGR of 0.07% from 2016 to 2022.
Browse the full report Tamoxifen: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 at http://www.credenceresearch.com/report/tamoxifen-market
Tamoxifen is the oldest and among the most prescribed selective estrogen receptor modulator for breast cancer treatment and management. Tamoxifen is approved for early stage, hormone receptor positive breast cancer in men and women, after surgery or chemotherapy to reduce recurrence risk, and for management of advanced stage or metastatic hormone-receptor positive breast cancer. Women at high risk of developing breast cancer also use Tamoxifen. Tamoxifen is at the maturity stage of product life cycle and is anticipated to experience decline in market growth in the light of introduction of advanced breast cancer management drugs.
Download sample research report @ http://www.credenceresearch.com/sample-request/57902
Table Of Content:
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
Chapter 2 Executive Summary
Chapter 3 Tamoxifen: Market Dynamics and Outlook
3.2 Breast Cancer: Key Statistics
3.3 Major Events Assessment
3.4 Market Dynamics
126.96.36.199 Advantages of Hormone Therapy Across Different Stages of Treatment
188.8.131.52 Widespread use as Adjuvant and Neo-Adjuvant Therapy
184.108.40.206 Growth in Tamoxifen-Resistant Breast Cancer
3.4.3 Opportunities ...
Chapter 6 Company Profiles
6.1 Astra Zeneca plc
6.1.1 Astra Zeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.2 Teva Pharmaceutical Industries Ltd.
6.2.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.3 Allergen plc
6.3.1 Allergen plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.4 Mylan Pharmaceuticals, Inc. ...
For the purpose of this study, the global tamoxifen market is categorized as follows:
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Rest of the World
North America is the largest regional market for tamoxifen drugs in 2015 and accounted for over 35%. High incidence of breast cancer, awareness about screening, prevention and management of breast cancer and favorable government policies are the prime factors allowing the growth of tamoxifen market in North America. The region is expected to retain its leas through the forecast period followed by Europe. The trends in European market are majorly determined by U.K., Germany, France and Belgium. Belgium is among the countries with the highest incidence of breast cancer, this market the country a promising market for tamoxifen drugs. U.K. and Germany are currently the largest country-level markets in Europe. Furthermore, Asia-Pacific and Rest of the World are estimated to register the fastest market growth during the forecast period due to growing recurrence of breast cancer and high prevalence of late-stage breast cancer detection. Rapid development of healthcare infrastructure is also for growth in these markets.
Request for customization research report @ http://www.credenceresearch.com/request-for-customization/57902